ArticleMammalian genome : official journal of the International Mammalian Genome Society2025
Multi-omics reveals that genes linked to succinylation regulate the onset of epilepsy through metabolic reprogramming.
Article in Mammalian genome : official journal of the International Mammalian Genome Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
The relationship between succinylation modification and epilepsy is not yet well defined, and the potential mediation of metabolic imbalance in its regulatory pathways requires deeper investigation. This study combines Mendelian randomization (MR) and single-cell transcriptomic techniques to investigate the causal interplay between succinylation-related genes, plasma metabolites, and epilepsy. Specifically, the eQTLGen and plasma metabolite databases are utilized for two-sample MR analysis, which evaluates genetic instrumental variables and quantifies causal effects. The two-step MR approach is applied to identify potential metabolic pathways mediating these genetic effects. This study integrates single-cell data from the temporal lobe of epilepsy patients to delineate cell-type-specific gene expression and regulatory networks. MR analysis identified that elevated expression of the CTBP1 gene significantly increases the risk of epilepsy (OR = 1.052, p = 0.0026). This pathogenic effect is mediated through the dysregulation of eight metabolites: a reduction in six neuroprotective sphingolipids and ceramide (β < 0), coupled with an accumulation of the pro-epileptic metabolite Methylsuccinate (β > 0). Among these, Sphingomyelin (d18:1/21:0, d17:1/22:0, d16:1/23:0) exhibited the highest mediation ratio (25.71%). Single-cell transcriptomics further revealed that CTBP1 is specifically highly expressed in excitatory neurons. In the epileptic temporal lobe, these neurons displayed rewired intercellular communication, primarily characterized by enhanced signaling via the NRG3-ERBB4 axis, alongside alterations in neuroimmune and metabolic pathways. This study provides the first integrated multi-omics evidence that CTBP1 may promote epileptogenesis through metabolic reprogramming and neuronal heterogeneity regulation, suggesting a potential role for CTBP1-mediated metabolic reprogramming in temporal lobe excitatory neurons in the disorder's pathology.
Indexed as
Identifiers
41361022What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.